Bildkälla: Stockfoto

ChromoGenics: Entering 2024 with the ambitious Skanska collaboration in focus - Redeye

Redeye provides an update on ChromoGenics following the company's Q4 2023 results. A weak quarter closed a tough 2023. But with recent successful capital increase, and a few good projects in the pipeline, 2024 looks promising.

Redeye provides an update on ChromoGenics following the company's Q4 2023 results. A weak quarter closed a tough 2023. But with recent successful capital increase, and a few good projects in the pipeline, 2024 looks promising.
Börsvärldens nyhetsbrev
ANNONSER